Vendor Intelligence Report: Planet Peptide

Published 12 Jun 2026. 28-page investigative report on who is behind Planet Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Planet Peptide is unusually identifiable for this market, but not uniformly reliable by product. The storefront ties to NEOS BIO, LLC in Bradenton, Florida, and Florida filings show a Chavez-family formation that later narrows to Ashley Hawk as sole manager. The founder memorial is materially corroborated; the older domain history is not evidence that the current supply chain has been operating since the mid-2010s.

Across 61 Finnrick lab tests, Planet Peptide posts 40 pass / 21 fail — an overall pass rate of 66%. Identity testing is clean in the supplied record, but quality is uneven. Ipamorelin is one of the cleaner signals on a small sample, while Tirzepatide and Semaglutide are more usable-but-verification-dependent than truly precise. CJC-1295 is the clear avoid signal, and the ratings fall under stricter grading where fill accuracy and purity are penalized harder.

The most buyer-relevant paperwork issue is a same-batch mismatch: a Chromate Semaglutide COA reports a much lower overfill than Finnrick later measured on samples associated with the same batch. That does not prove falsification or intent, but it does make a single posted COA too thin for dose-sensitive purchasing. The report also flags a legacy NEOS BIO domain listed for sale, policy contradictions around refunds and age gating, and an unusual Klarna payment surface.

Inside the full report:

  • Per-product Finnrick pass/fail interpretation, rating trajectories, and methodology-divergence charts for all 9 products
  • Florida SOS formation, amendment, trademark, and Ashley Chavez-to-Ashley Hawk control records
  • Wayback, RDAP, DNS, certificate, and domain-confusion analysis for planetpeptide.com, planetpeptide.net, and neosbio.com
  • Chromate COA #23858 comparison against Finnrick same-batch Semaglutide findings
  • Policy and buyer-recourse analysis covering returns, age gate language, sterility disclaimers, and chargeback posture
  • Community-reputation and affiliate/promotion scan, including forum narratives and coupon-site limits

Risk assessment

  • CJC-1295 product-quality risk — high: CJC-1295 has 0 pass / 4 fail and a 19.46% Finnrick rating; do not buy without fresh lot-specific independent testing.
  • Dose-accuracy risk in Tirzepatide, Retatrutide, and Semaglutide — high: High-demand GLP-1 products show repeated Finnrick failures: Tirzepatide 13/19 pass, Retatrutide 8/15 pass, Semaglutide 6/8 pass, with same-batch COA disagreement on Semaglutide.
  • COA-verification and QA-transparency risk — medium: Chromate COA #23858 for Semaglutide batch 004012025 is a single-lab result without endotoxin/MS confirmation in the supplied COA, and its quantity result did not align with Finnrick's same-batch record.
  • Brand-confusion / legacy-domain risk — medium: neosbio.com, tied to older NEOS BIO contacts/branding, is listed for sale; no authorized-reseller/official-channel list or anti-counterfeit program was found.
  • Support and legal-policy risk — medium: Terms conflict on returns and age requirements and state human/animal-use emails will not be answered, reducing buyer recourse after adverse events.
  • Business-continuity risk — medium: After August 2024 amendments Ashley Hawk is the sole manager/registered agent; no succession or backup operating control surfaced.